

Patrizia Borsotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10193647/publications.pdf>

Version: 2024-02-01

26
papers

2,314
citations

331670

21
h-index

610901

24
g-index

26
all docs

26
docs citations

26
times ranked

3374
citing authors

#	ARTICLE	IF	CITATIONS
1	Shedding of the Matrix Metalloproteinases MMP-2, MMP-9, and MT1-MMP as Membrane Vesicle-Associated Components by Endothelial Cells. <i>American Journal of Pathology</i> , 2002, 160, 673-680.	3.8	502
2	Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. <i>American Journal of Pathology</i> , 2000, 157, 1703-1711.	3.8	322
3	Inhibition of Angiogenesis and Murine Hemangioma Growth by Batimastat, a Synthetic Inhibitor of Matrix Metalloproteinases. <i>Journal of the National Cancer Institute</i> , 1995, 87, 293-298.	6.3	220
4	Bioavailability of VEGF in Tumor-Shed Vesicles Depends on Vesicle Burst Induced by Acidic pH. <i>Neoplasia</i> , 2006, 8, 96-103.	5.3	168
5	Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin. <i>Clinical Cancer Research</i> , 2004, 10, 4813-4821.	7.0	144
6	Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. <i>Leukemia</i> , 2003, 17, 52-59.	7.2	142
7	Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. <i>Cancer Research</i> , 2003, 63, 1534-7.	0.9	94
8	Antiangiogenic activity of aplidine, a new agent of marine origin. <i>British Journal of Cancer</i> , 2004, 90, 2418-2424.	6.4	82
9	Vascular Disrupting Activity of Tubulin-Binding 1,5-Diaryl-1 <i>H</i> -imidazoles. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7906-7910.	6.4	65
10	The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. <i>Clinical Cancer Research</i> , 2006, 12, 1839-1849.	7.0	54
11	p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. <i>Oncogene</i> , 2001, 20, 7293-7300.	5.9	51
12	Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMPâ€1 and TIMPâ€2 and tumor thrombospondinâ€1. <i>International Journal of Cancer</i> , 2015, 136, 721-729.	5.1	50
13	Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. <i>Clinical Cancer Research</i> , 2002, 8, 1182-8.	7.0	50
14	Thrombospondinâ€1 is part of a Slugâ€independent motility and metastatic program in cutaneous melanoma, in association with <sc>VEGFR</sc>â€1 and <sc>FGF</sc>â€2. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 73-81.	3.3	45
15	Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. , 1999, 188, 76-81.		44
16	Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. <i>Experimental Cell Research</i> , 2000, 258, 384-394.	2.6	43
17	Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 879-887.	2.3	37
18	The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2). <i>Angiogenesis</i> , 2019, 22, 133-144.	7.2	37

#	ARTICLE	IF	CITATIONS
19	Inhibition of matrix metalloproteinases by overexpression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas. <i>International Journal of Cancer</i> , 2001, 91, 241-247.	5.1	29
20	Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies. <i>Neoplasia</i> , 2012, 14, 846-856.	5.3	28
21	Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. <i>Carcinogenesis</i> , 2019, 40, 303-312.	2.8	28
22	Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies. <i>Clinical Cancer Research</i> , 2005, 11, 2720-2726.	7.0	23
23	CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy. <i>Cells</i> , 2020, 9, 952.	4.1	23
24	Effect of alltrans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. <i>Leukemia</i> , 1997, 70, 72-77.		21
25	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts. <i>Connective Tissue Research</i> , 2015, 56, 355-363.	2.3	10
26	Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. <i>Matrix Biology</i> , 2021, 103-104, 22-36.	3.6	2